9 METERS BIOPHARMA, INC. (INNT) [Rocket]

Overview

9 METERS BIOPHARMA, INC. (INNT)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
07/21/2023	144	Form 144 - Report of proposed sale of securities:
07/19/2023	144	Form 144 - Report of proposed sale of securities:
07/18/2023	8-K	Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direc...
06/16/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/19/2023	PRE 14A	Form PRE 14A - Other preliminary proxy statements:
05/19/2023	8-K	Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
05/15/2023	10-Q	Quarterly Report for the period ended March 31, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	4.1	8.3
Revenue growth						-100.0%	-50.8%	-27.1%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	3.3	7.8
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.4
Gross margin							18.1%	5.2%
Sales and marketing							2.4	2.9
Research and development	31.0	22.0	10.9	13.7	7.6	4.0	0.3	0.3
General and administrative	11.0	9.7	10.5	10.6	10.7	7.2	4.0	3.6
EBITA	-41.6	-31.7	-28.6	-25.5	-18.2	-11.2	-5.8	-6.4
EBITA margin							-143.0%	-77.5%
Amortization of intangibles							0.1	0.1
EBIT	-41.6	-31.7	-28.6	-25.5	-18.2	-11.2	-5.9	-6.5
EBIT margin							-146.2%	-78.2%
Pre-tax income	-43.8	-36.8	-61.5	-27.0	-24.2	-11.6	-6.2	-8.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-43.8	-36.8	-61.5	-27.0	-24.2	-11.6	-6.2	-8.7
Net margin							-152.8%	-105.7%

Diluted EPS	($3.38)	($3.03)	($0.58)	($0.81)	($0.98)	($0.98)	($11.26)	($2.65)
Shares outstanding (diluted)	13.0	12.2	105.6	33.3	24.8	11.9	0.6	3.3

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.